Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin and Simvastatin with Fulvestrant in ER+ Breast Cancer
NCT03192293Phase 2Unknown
- Sponsor
- National University Hospital
- Start
- Jan 2017
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of liquid metformin (Aspargo Labs) and simvastatin in breast cancer, sponsored by National University Hospital. Primary endpoint: Clinical Benefit Rate at 24 weeks. Status: unknown.
02
Drugs
liquid metformin (Aspargo Labs)simvastatin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03192293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03192293.